Salute e Benessere

Surgical Sutures Market Size to Grow USD 5306.1 Million by 2029 at a CAGR of…

Claim Your Free Sample Now: Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-28G9783/Global_Surgical_Sutures_Market_Insights_Forecast_to_2028 Major Factors Driving The Growth Of The Surgical Sutures Market The increasing number of surgical procedures performed worldwide, improvements in suture technology and materials, the growing geriatric population that requires more medical interventions, and the rise in chronic illnesses and trauma cases...
PR Newswire
10/01/2024

PCM Trials Acquires Netherlands-Based Clinical Trial Service B.V., Becoming the…

CTS was founded in 1993 in Losser, Netherlands, and quickly became a preferred provider of mobile research nurses for some of the biggest names in the pharmaceutical industry. The organization has a network of over 40 mobile nurse partners that it manages as part of its robust network of local country nursing providers, which provide quality solutions by highly screened, selected, managed, and trained research nurses in more than 80 countries. In addition to handling staffing needs for mobile…
PR Newswire
10/01/2024

Herbal Extract Products Market to Reach $85,120.9 Million, Globally, by 2032 at…

PORTLAND, Ore., Jan. 10, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Herbal Extract Products Market by Type (Alcohol-Based Extracts, Powder-Based Extracts, Oil-Based Extracts), by Raw Materials (Berries, Bark, Leaves, Roots, Flowers, Fruits, Aromatic Herbs, Other), by End-use Industry (Food and Beverage, Cosmetics and Personal Care, Pharmaceuticals, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global…
PR Newswire
10/01/2024

Preimplantation Genetic Testing Market Size to Grow USD 528.9 Million by 2029 at…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Othe-0H192/preimplantation_genetic_testing_market Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Othe-0H192/preimplantation_genetic_testing_market Major Factors driving the growth of Preimplantation Genetic Testing Market There is a greater need for PGT as a result of expanding acceptance of in vitro fertilization (IVF), an increase in the frequency of reproductive issues...
PR Newswire
10/01/2024

Global Probiotics Market to Hit $126.34 Billion by 2030, Recording a Strong…

Get a Sample PDF of the Report:https://www.kingsresearch.com/request-sample/probiotics-market-173 Get a Sample PDF of the Report:https://www.kingsresearch.com/request-sample/probiotics-market-173 Trending Now: Bifidice Secures$850,000in Funding for Probiotic Health Advancements January 2024 : Chilean probiotics company Bifidice successfully raised$850,000in funding. The investment was primarily led by Südlich Capital, with contributions from angel investors Thomas...
PR Newswire
10/01/2024

Neuropathic Pain Market to Reach $13.25 billion, Globally, by 2032 at 5.6% CAGR…

Request Sample of the Report on Neuropathic Pain Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/5447 Request Sample of the Report on Neuropathic Pain Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/5447 Prime determinants of growth Rise in diabetic neuropathy, rise in prevalence of chronic diseases, rise in demand of drugs for neuropathic pain, and rise in geriatric population drive the growth of the global neuropathic pain...
PR Newswire
10/01/2024

Biologics Contract Manufacturing Market Size to Hit USD 58 Billion 2035 | Roots…

Global Biologics Contract Manufacturing Market Overview Global Biologics Contract Manufacturing Market Overview The global biologics contract manufacturing market is anticipated to grow overUSD 19.6 billionin 2023 and is estimated to reachUSD 58 billionby 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 9% during the forecast period 2023-2035. Biologics contract manufacturing has recently garnered attention due to the rising demand for cell and...
PR Newswire
10/01/2024

Oligonucleotide Synthesis Market to Exceed 9.9 billion by 2035 Say, Roots…

LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035). LONDON,Jan. 10, 2024/PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worthUSD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035...
PR Newswire
10/01/2024

Hollyland LARK M2: Unparalleled Lightweight Wireless Lavalier Microphone…

Advanced Antenna for Reliable Long Range Transmission Advanced Antenna for Reliable Long Range Transmission The LARK M2 is not only perfect for general content creation, but also for other real-time audio and video activities, such as live entertainment, distance learning, social media, event planning, weddings, presentations, live streaming, and more. The LARK M2 eliminates messy wires, providing a truly wireless recording experience. The Lightning version connects to classic iPhones,...
PR Newswire
10/01/2024

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating…

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here:videoOCALA, Fla., Jan.10, 2024(GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that enrollment is open at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM's Ampligen ®(rintatolimod) with AstraZeneca's anti-PD-L1...
Nasdaq GlobeNewswire
10/01/2024

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Click here to view the custom infographic of the Lexaria Bioscience Corp. editorial. Click here to view the custom infographic of the Lexaria Bioscience Corp.editorial. Diabetes and Obesity: A Growing Concern with a Glimmer of Hope Imagine a silent storm raging inside countless bodies, a chronic battle against rising blood sugar. This is the reality for the 422 million people worldwide battling diabetes, a disease with tentacles that reach far beyond elevated glucose levels...
PR Newswire
10/01/2024

A New Study Shows GlycoMark is a Novel Biomarker of SGLT-2i Adherence

This new study data is consistent with previously reported studies which indicate that 1,5-anhydroglucitol may be useful for evaluating short-term effectiveness and assessing patient compliance of SGLT-2i drugs. One such study, "GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors," was recently presented at the American Diabetes Association (ADA) Scientific Sessions. In this study, clinical investigators from Aveon Health (Scottsdale, AZ) conducted a review of…
PR Newswire
10/01/2024

Cardiovascular Drugs Market Size & Share to Surpass USD 195.6 billion, at a 3.8%…

Researchers are working on new drug classes and therapies to treat cardiovascular disease, like gene therapies, RNA-based therapeutics, and stem cell therapies. By using these innovations, traditional medications could be rendered less effective and less durable. With digital health technologies like wearables and remote monitoring, cardio conditions could be better managed. Monitoring in real-time, coupled with data analytics, could lead to more proactive and personalized interventions. ...
PR Newswire
10/01/2024

More accurate tumour treatment thanks to superconductive ASG Superconductors…

With the prototype presented today in Germany at Oncoray - the National Centre for Radiation Research in Oncology, it will in fact be possible, for the first time in the world, to study the extent to which the accuracy of proton therapy can be improved with the guidance of real-time MRI for the whole body. Head of the research group 'Experimental MR-integrated Proton Therapy' Prof. Aswin Hoffmann, with whom ASG engineers have been collaborating on the development of the new system over the…
PR Newswire
10/01/2024

New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted…

Lack of effective treatment for myofibrillar myopathy Lack of effective treatment for myofibrillar myopathy Myofibrillar myopathy, primarily caused by genetic mutations, including the BAG3 gene, is a rare hereditary neuromuscular disorder with symptoms resembling muscular dystrophy. It typically manifests during adolescence and is characterised by severe clinical symptoms, including progressive muscle weakness, muscle atrophy, motor impairment, muscle stiffness, respiratory muscle...
PR Newswire
10/01/2024

Nanoflex Robotics Receives ISO 13485 Certification

The innovative medical robotic startup achieved the globally recognized ISO 13485 certification in December 2023 The ISO 13485 certification is the global standard for quality management systems within the medical device industry. To become certified, companies must demonstrate that important components are designed and manufactured in accordance with stringent regulatory standards.The certification represents Nanoflex Robotics' commitment to upholding high standards throughout its...
Nasdaq GlobeNewswire
10/01/2024

Pulsenmore Receives Brazilian ANVISA Approval for Its Prenatal Home Ultrasound…

Pulsenmore's revolutionary home ultrasound technology empowers pregnant women to conduct ultrasound imaging scans from the comfort of their homes, using their personal smartphones connected to a dedicated device and application. These scans are seamlessly transmitted to remote hospitals or clinics for evaluation, focusing on crucial fetal vitality parameters. Pulsenmore's revolutionary home ultrasound technology empowers pregnant women to conduct ultrasound imaging scans from the comfort of...
PR Newswire
10/01/2024

STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab…

Marketing authorization issued in European Economic Area for Uzpruvo ®, the first biosimilar to Stelara ®, a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves way for biosimilar competition in the approximately €2.5 billion (US$2.7 billion) EU ustekinumab market as soon as possible after expiry of intellectual-property rights in July 2024Approval for the Uzpruvo biosimilar is based on comprehensive package comprising analytical,...
Nasdaq GlobeNewswire
10/01/2024

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its…

Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics said: "Glioblastoma is the most aggressive and most common type of malignant brain tumour in adults, with a very poor prognosis for survival and currently no cure. 123I-ATT001 is a targeted Auger electron therapy that has demonstrated promising pre-clinical results, and we are delighted to be in a position to file for clinical trial authorisation in the UK so soon after integrating Theragnostics into Ariceum Therapeutics. Not…
PR Newswire
10/01/2024

Nexstim Receives NBS System 5 Order from Healthcare Services Group in the US

Press release, Helsinki, 10 January 2024 at 10 AM (EET) Nexstim Receives NBS System 5 Order from Healthcare Services Group in the US Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a healthcare services group based in the US. The system will mainly be used in neurosurgery for presurgical mapping of the brain.Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the…
Nasdaq GlobeNewswire
10/01/2024

SciBase: Letter from the CEO

Together with our expert advisor, Pinnacle Health Group, we have developed a clear and efficient reimbursement strategy. This has already led to two Medicare Administrative Contractors (MACs), active across 13 states, adopting routine reimbursement for the use of Nevisense. As we now accelerate our efforts, they are reinforced by the endorsement of key opinion leaders and collaborations with premier dermatology networks across several states. Among our KOLs are Dr. Darrell Rigel, the creator of…
PR Newswire
10/01/2024

Kanazawa University research: Researchers observe what ubiquitination hinges on

Previous studies have identified a number of enzymes that facilitate ubiquitination, including an enzyme that activates ubiquitin (E1), an enzyme that conjugates it (E2), and an enzyme that catalyzes ubiquitin protein joining (i.e. a ligase, E3) to target protein (Fig. 1). The HECT-type E3 ligase is characterized by a HECT domain that comprises an N lobe with the E2-binding site and a C lobe with a catalytic Cys residue, a flexible hinge connects the two lobes, leading to the hypothesis that…
PR Newswire
10/01/2024

Get a Glimpse of the Future: Guangzhou CIFF 2024 to Showcase Cutting-Edge Office…

The 2024 edition will expand to utilize Area A, B and D of the Canton Fair Complex, covering a total area of over 240,000 square meters. With an estimated participation of around 1,100 companies, the event focuses on three key themes, namely boundless office, healthy seating, and diverse commercial space, offering unique insights and solutions for the evolving workspace. Furthermore, the exhibition will feature the Trendy Design Hall (Hall 5.2) and the International Brand Hall (Hall 20.2)…
PR Newswire
10/01/2024

QN Europe Joins Luxembourg's Premier Direct Selling Association

Mr. Kirikos Lazarou, Managing Director of QN Europe, emphasizes this alignment stating: "Joining AVDL is a clear indication of our dedication to excellence and ethical operations in Luxembourg and across Europe. We look forward to working alongside AVDL and its members to enhance the direct selling industry's growth and reputation in Luxembourg." Mr.Kirikos Lazarou, Managing Director of QN Europe, emphasizes this alignment stating: "Joining AVDL is a clear indication of our…
PR Newswire
10/01/2024
Altri  Comunicati